ReViral raises $55M series B

ReViral Ltd. (Stevenage, U.K.) raised $55 million in a series B round co-led by new investors New Leaf Venture Partners and Novo Ventures. Also participating in the round was fellow new investor Perceptive Advisors and existing investors Andera Partners, OrbiMed and Brace Pharma Capital.

In February, ReViral said lead candidate RV521 met the primary and all secondary endpoints in a Phase IIa respiratory syncytial virus (RSV) challenge trial in healthy adult volunteers (see "ReViral's Oral RSV Candidate Meets in Phase IIa")...